- Home
- WHWK vs CNTX Comparison
WHWK vs CNTX Comparison
Compare WHWK & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | CNTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 102.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WHWK | CNTX |
|---|---|---|
| Price | $2.55 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 203.1K | ★ 389.2K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.49 |
| 52 Week High | $3.81 | $1.61 |
Technical Indicators
Market Signals| Indicator | WHWK | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 41.40 |
| Support Level | $2.10 | $1.00 |
| Resistance Level | $2.36 | $1.18 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 100.00 | 11.80 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.